Johnson and Johnson's quarterly profit rises 3.3 percent
Johnson and Johnson reported a 3.3 percent rise in quarterly profit, as higher sales of cancer drugs Zytiga and Darzalex helped offset pressure on its blockbuster rheumatoid arthritis treatment Remicade.
The healthcare conglomerate's net earnings rose to $3.95 billion, or $1.45 per share, in the second quarter, from $3.83 billion, or $1.40 per share, a year earlier.
Sales rose to $20.83 billion from $18.84 billion.
(Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)